Discriminative stimulus and subjective effects of opioids with mu and kappa activity: Data from laboratory animals and human subjects

被引:47
作者
Dykstra, LA
Preston, KL
Bigelow, GE
机构
[1] NIDA, NIH, INTRAMURAL RES PROGRAM, BALTIMORE, MD 21224 USA
[2] JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21224 USA
关键词
opioids; discriminative stimulus; humans;
D O I
10.1007/s002130050208
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Although a large and rich body of data is available regarding the discriminative stimulus effects of opioids in laboratory animals and human subjects, it has been difficult to reconcile the data obtained from these two different sources. Therefore, the purpose of this review is to bring together data from both animal and human laboratories and systematically to compare the discriminative stimulus effects of opioids, in particular those with activity at both mu and kappa opioid receptor types (i.e., the mixed action opioids). The data that can be collected from laboratory animals differ from the data that can be collected in human subjects, In general, the advantage of studies in laboratory animals is that they can investigate very broad dose ranges of opioids as well as some very selective opioids that are not available for investigation in human subjects, Although investigations in human subjects are limited by the compounds and doses available for examination,;he advantage of these studies is that they can examine the subjective as well as the discriminative stimulus effects of opioids. Taken together, studies conducted in laboratory animals and human subjects indicate that the mixed action opioids are best classified as intermediate efficacy mu agonists with additional activity through other non-mlr, possibly kappa opioid systems.
引用
收藏
页码:14 / 27
页数:14
相关论文
共 79 条
[1]  
[Anonymous], PROGR REPORT STUDIES
[2]  
BERTALMIO AJ, 1987, J PHARMACOL EXP THER, V243, P591
[3]  
BICKEL WK, 1989, J PHARMACOL EXP THER, V251, P1053
[4]  
BIGELOW GE, 1996, NIDA RES MONOGR, V162, P344
[5]  
Brandt MR, 1996, J PHARMACOL EXP THER, V277, P960
[6]  
BUTELMAN ER, 1995, J PHARMACOL EXP THER, V272, P845
[7]   THE OPIOID RECEPTOR-BINDING OF DEZOCINE, MORPHINE, FENTANYL, BUTORPHANOL AND NALBUPHINE [J].
CHEN, JC ;
SMITH, ER ;
CAHILL, M ;
COHEN, R ;
FISHMAN, JB .
LIFE SCIENCES, 1993, 52 (04) :389-396
[8]  
CRAFT RM, 1990, J PHARMACOL EXP THER, V252, P945
[9]  
DYKSTRA LA, 1990, J PHARMACOL EXP THER, V254, P245
[10]  
DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413